[Comment] Shaping opportunities for future clinical trials in tuberculosis

One key aspect of current trials in tuberculosis therapy is to evaluate shorter regimens.1 For decades, drug-sensitive tuberculosis has been treated with a 6-month regimen, but more recent evidence supports an alternative 4-month regimen containing rifapentine and moxifloxacin.2 However, the 6-month regimen is still widely used globally due to challenges, such as cost and licensing status, which complicate the procurement of rifapentine and moxifloxacin.